Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: Results of a randomized, double-blind, placebo- and active-controlled phase 2 trial

  • Calhoun D
  • White W
  • Krum H
 et al. 
  • 23


    Mendeley users who have this article in their library.
  • 119


    Citations of this article.


LCI699, a novel inhibitor of aldosterone synthase, reduces serum aldosterone, and may have benefit in the treatment of hypertension.

Author-supplied keywords

  • blood pressure
  • hypertension
  • inhibitors
  • trials

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free